In conclusion, our study characterised the novel HDAC inhibitor CG200745, which demonstrated anti-tumour effects against cholangiocarcinoma cells in vitro and in vivo with additive and synergistic effects when used in combination with standard chemotherapy drugs. Here, HDAC9 is linked to neoplasm.